Robert W. Baird Reaffirms Neutral Rating for Phreesia (NYSE:PHR)

Key Points

• Robert W. Baird reaffirmed a neutral rating on Phreesia and cut its price target to $10 from $25, implying roughly a 12.5% downside from the current share price.
• Phreesia missed EPS ($0.02 vs. $0.07 est.), issued softer FY2027 guidance ($510–$520M), and saw shares plunge about 22%, prompting multiple analyst target cuts though the consensus remains a Moderate Buy with an average target of $22.71.
• Insiders sold roughly 70,358 shares (~$1.12M) last quarter while institutional investors own about 92.1% of the stock, concentrating ownership and potentially affecting trading dynamics.

Phreesia (NYSE:PHR - Get Free Report)'s stock had its "neutral" rating reaffirmed by Robert W. Baird in a research report issued on Tuesday, Marketbeat.com reports. They currently have a $10.00 price target on the stock, down from their prior price target of $25.00. Robert W. Baird's price objective suggests a potential downside of 12.54% from the company's current price.

A number of other research firms have also issued reports on PHR. Royal Bank Of Canada started coverage on Phreesia in a research report on Friday, January 9th. They set a "moderate buy" rating and a $26.00 price objective for the company. Needham & Company LLC cut their target price on Phreesia from $35.00 to $14.00 and set a "buy" rating on the stock in a research note on Tuesday. JPMorgan Chase & Co. reduced their price target on shares of Phreesia from $29.00 to $24.00 and set an "overweight" rating for the company in a report on Friday, February 20th. Citigroup lowered their price target on shares of Phreesia from $29.00 to $25.00 and set a "buy" rating for the company in a research report on Friday, January 9th. Finally, Wells Fargo & Company dropped their price objective on shares of Phreesia from $30.00 to $25.00 and set an "overweight" rating on the stock in a report on Thursday, March 26th. Thirteen equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $22.71.

Phreesia Price Performance

PHR opened at $11.43 on Tuesday. The company has a quick ratio of 2.44, a current ratio of 2.44 and a debt-to-equity ratio of 0.01. The company's 50-day moving average price is $12.51 and its 200 day moving average price is $17.68. Phreesia has a fifty-two week low of $10.75 and a fifty-two week high of $32.76. The firm has a market cap of $689.36 million, a price-to-earnings ratio of -114.33 and a beta of 0.67.

Phreesia (NYSE:PHR - Get Free Report) last issued its earnings results on Monday, March 30th. The company reported $0.02 EPS for the quarter, missing analysts' consensus estimates of $0.07 by ($0.05). The company had revenue of $127.07 million during the quarter, compared to analyst estimates of $126.75 million. Phreesia had a negative net margin of 1.16% and a negative return on equity of 1.31%. The business's revenue was up 15.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.11) earnings per share. As a group, sell-side analysts expect that Phreesia will post -1.1 earnings per share for the current year.

Insiders Place Their Bets

In other news, General Counsel Allison C. Hoffman sold 6,585 shares of the stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $17.01, for a total value of $112,010.85. Following the completion of the transaction, the general counsel owned 174,762 shares of the company's stock, valued at approximately $2,972,701.62. This represents a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Balaji Gandhi sold 8,009 shares of the firm's stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $17.01, for a total value of $136,233.09. Following the transaction, the chief financial officer directly owned 156,231 shares in the company, valued at $2,657,489.31. This trade represents a 4.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 70,358 shares of company stock worth $1,123,569. Insiders own 5.50% of the company's stock.

Institutional Trading of Phreesia

A number of hedge funds and other institutional investors have recently made changes to their positions in PHR. Federated Hermes Inc. acquired a new stake in shares of Phreesia in the 3rd quarter worth approximately $32,000. Van ECK Associates Corp increased its stake in shares of Phreesia by 78.7% during the fourth quarter. Van ECK Associates Corp now owns 2,502 shares of the company's stock valued at $42,000 after acquiring an additional 1,102 shares during the period. Asset Management One Co. Ltd. bought a new stake in Phreesia during the third quarter worth approximately $45,000. Rockefeller Capital Management L.P. raised its holdings in Phreesia by 354.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 2,755 shares of the company's stock worth $47,000 after purchasing an additional 2,149 shares in the last quarter. Finally, KBC Group NV lifted its position in Phreesia by 83.4% in the fourth quarter. KBC Group NV now owns 3,449 shares of the company's stock worth $58,000 after purchasing an additional 1,568 shares during the period. 92.10% of the stock is currently owned by institutional investors.

Key Headlines Impacting Phreesia

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Company reported positive GAAP net income and strong free cash flow for the fiscal year — exceeded internal targets including crossing $100M of Adjusted EBITDA and roughly $50M+ of free cash flow, a proof point for profitability and capital-generation that can support valuation. Phreesia Announces Fourth Quarter Fiscal 2026 Results
• Positive Sentiment: Management highlighted record revenue growth and strategic initiatives on the Q4 call, indicating underlying demand and execution on product/partnership priorities that investors view as longer-term upside. Phreesia Inc (PHR) Q4 2026 Earnings Call Highlights: Record Revenue Growth and Strategic ...
• Neutral Sentiment: Full earnings-call transcript is available for detail seekers — useful for investors who want management’s color on drivers, margin improvement, and the AccessOne integration timeline. Phreesia, Inc. (PHR) Q4 2026 Earnings Call Transcript
• Neutral Sentiment: Several analysts revised expectations heading into the print, lowering EPS/forecast assumptions — shows sentiment was already shifting and likely amplified intraday moves. Top Wall Street Forecasters Revamp Phreesia Expectations Ahead Of Q4 Earnings
• Negative Sentiment: Management cut near-term outlook: FY2027 revenue was guided to $510M–$520M and executives warned of headwinds from the network solutions business and integration-related pressure from AccessOne — a driver of the recent sell-off. Phreesia outlines $510M–$520M revenue target for 2027 amid network solutions headwinds and AccessOne integration
• Negative Sentiment: Market reaction: shares plunged after the EPS miss and guidance cut (reports of a ~22% drop and all-time lows in some sessions) — short-term momentum and sentiment risk remain. Phreesia shares tumble 22% on earnings miss, slashed guidance

About Phreesia

Phreesia, Inc NYSE: PHR is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company's cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.